KALEO INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KALEO INC, and when can generic versions of KALEO INC drugs launch?
KALEO INC has four approved drugs.
There are thirty-nine US patents protecting KALEO INC drugs.
There are one hundred and forty-four patent family members on KALEO INC drugs in fifteen countries and one supplementary protection certificate in one country.
Drugs and US Patents for KALEO INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kaleo Inc | NALOXONE HYDROCHLORIDE (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 215457-001 | Feb 28, 2022 | DISCN | Yes | No | 9,022,022 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | 10,335,549 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Kaleo Inc | NALOXONE HYDROCHLORIDE (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 215457-001 | Feb 28, 2022 | DISCN | Yes | No | 9,737,669 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 8,361,029 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for KALEO INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2012508081 | ⤷ Sign Up |
Mexico | 2007005946 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2006083876 | ⤷ Sign Up |
Japan | 2008520339 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for KALEO INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.